iX Biopharma

iX Biopharma Ltd specialises in the development and commercialisation of innovative therapies for pain management and men's health. The company leverage on patented sublingual drug delivery technology. Ixbiopharma operates in a fully - integrated business model from drug development to manufacturing and supply.

iX Biopharma Ltd has today lodged its preliminary offer document with the Singapore Exchange Securities Trading Limited, in connection with a proposed listing on Catalist.

A copy of the lodged preliminary offer document may be obtained from this link: http://www.sgx.com/wps/wcm/connect/sgx_e...pharma+Ltd

CIMB Bank Berhad, Singapore Branch is the issue manager and sponsor, while CIMB Securities (Singapore) Pte. Ltd. is the underwriter and placement agent of this IPO.

Lai liao lo.. IX biopharma today IPO...

iX Biopharma Ltd., a late-stage specialty pharmaceutical company focused on the development and commercialisation of innovative therapies for pain management and male erectile dysfunction, has received strong interest from institutional and retail investors for its initial public offering (“IPO”).

The offering comprised 65.5 million Invitation Shares (“Invitation Shares”) priced at 46 cents each. Of these, 64.5 million shares were available by way of placement (“Placement Shares”), while one million shares were made available for public subscription (“Offer Shares”).

At the close of the IPO at 12.00 noon on 20 July 2015, there were 854 valid applications received for the Offer Shares. In total, these applicants applied for an aggregate of approximately 24.7 million Offer Shares, with application monies received amounting to approximately $11.3 million. All Placement Shares have also been fully subscribed for, raising approximately $29.7 million.


Huat BIG BIG

I have created a new thread for the company, and split the relevant post from previous thread.

Thanks

Regards
Moderator

A good summary of the company.

4 Things You Need To Know About The Newly-Listed iX Biopharma Ltd

https://www.fool.sg/2015/07/22/4-things-...harma-ltd/

iX Biopharma Ltd. (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that its Phase 2a and 2b clinical trials for its lead product, WafermineTM, have proven successful. The results confirmed a rapid onset of pain relief, along with good tolerability. WafermineTM, is one of three iX Biopharma products currently under development and the world’s first oral-sublingual analgesic employing ketamine as its active compound. The clinical trials, conducted over the past one year, were designed to demonstrate the effectiveness and rapid onset of action of WafermineTM, and to determine the dosage scheme for the pivotal Phase 3 clinical trials.

is this listed in hong kong?

(28-09-2015, 02:49 PM)Raks Wrote: is this listed in hong kong?

Listed in Sg .

One of my Dealer is a Very Interesting Guy because when I told I wanted to Buy IX @ 0.30 he told me that he have to look for the stock....then I brought more lower....then when it was profitable I cashed out because it may not suit my interest !

But now above 0.40...my Dealer keep recommending to buy and hold for long term....my thoughts was IPO was 0.46....books may be still in the red...those who chased up during IPO opening will be rushing to sell if they still have it ! So I told him I will take a look at lower prices below 0.40...and if the price fly up then too bad !!!

iX Biopharma Obtains Approval and Registration of Wafesil for the Treatment of Male Erectile Dysfunction in Australia

Highlights :
* First sublingual wafer sildenafil product for male erectile dysfunction available in Australia
* First product in iX Biopharma’s pharmaceutical pipeline utilising WaferiX to receive approval and registration

iX Biopharma Ltd. announced the approval by Therapeutic Goods Administration ("TGA"), the regulatory authority in Australia, for WAFESIL (sublingual sildenafil wafer) formerly referred to as PheoniX, for the treatment of male erectile dysfunction. WAFESIL is a new dose form of sildenafil delivered using iX Biopharma’s proprietary drug delivery technology, WaferiX, which consists of a fast-dissolving wafer placed sublingually (under the tongue), allowing sildenafil to be administered safely, conveniently and rapidly into the blood stream. WAFESIL is the Group’s first pharmaceutical product utilising WaferiX to reach approval and registration.

Approximately 20% of Australian men greater than 40 years suffer from male erectile dysfunction with a significantly increased risk with aging and cardiovascular disease. “The launch of WAFESIL will provide new treatment options to doctors to help them serve an estimated one million men in Australia who are diagnosed with male erectile dysfunction, especially those who have an aversion to swallowing tablets”, said Ms Eva Tan, Commercial Director. “There is tremendous opportunity for us to establish an important new market for WAFESIL, given its status as a halal product and the only sublingual sildenafil product in Australia”.

“The approval of WAFESIL affirms the utility of our WaferiX drug delivery technology and demonstrates our ability to bring our products from clinical development to registration and launch,” said Dr Janakan Krishnarajah, Chief Medical Officer.

WAFESIL is available in dosage strengths of 25 mg and 50 mg in pack sizes of 4, 8 and 12 wafers. WAFESIL will be supplied to the market via wholesaler and pharmacy channels.

More details in http://infopub.sgx.com/FileOpen/Press%20...eID=511190